Skip to main content
. 2020 Sep 3;95(11):2382–2394. doi: 10.1016/j.mayocp.2020.08.038

Table 3.

Laboratory Markersa

Lenzilumab group (n=12) Control group (n=27) P
CRP reduction 135.8 -0.95 .01
IL-6 reduction 20.1 na na
ALC increase 0.46×109/L 0.03×109/L .04
PLT increase 52.5 63.2 .61
a

ALC = absolute lymphocyte count; CRP = C-reactive protein; IL-6 = interleukin 6; na = not available; PLT = platelet count.